Literature DB >> 26033733

Increased Vancomycin Susceptibility in Mycobacteria: a New Approach To Identify Synergistic Activity against Multidrug-Resistant Mycobacteria.

Karine Soetaert1, Céline Rens2, Xiao-Ming Wang1, Jacqueline De Bruyn2, Marie-Antoinette Lanéelle3, Françoise Laval3, Anne Lemassu3, Mamadou Daffé3, Pablo Bifani4, Véronique Fontaine2, Philippe Lefèvre5.   

Abstract

Mycobacterium tuberculosis is wrapped in complex waxes, impermeable to most antibiotics. Comparing Mycobacterium bovis BCG and M. tuberculosis mutants that lack phthiocerol dimycocerosates (PDIM) and/or phenolic glycolipids with wild-type strains, we observed that glycopeptides strongly inhibited PDIM-deprived mycobacteria. Vancomycin together with a drug targeting lipid synthesis inhibited multidrug-resistant (MDR) and extensively drug-resistant (XDR) clinical isolates. Our study puts glycopeptides in the pipeline of potential antituberculosis (TB) agents and might provide a new antimycobacterial drug-screening strategy.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26033733      PMCID： PMC4505240          DOI： 10.1128/AAC.04856-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

1.  Biochemical and immunological characterization of a cpn60.1 knockout mutant of Mycobacterium bovis BCG.

Authors:  Xiao-Ming Wang; Changlong Lu; Karine Soetaert; Catherine S'Heeren; Priska Peirs; Marie-Antoinette Lanéelle; Philippe Lefèvre; Pablo Bifani; Jean Content; Mamadou Daffé; Kris Huygen; Jacqueline De Bruyn; Ruddy Wattiez
Journal:  Microbiology (Reading)       Date:  2010-12-02       Impact factor: 2.777

2.  Synergic activity of D-cycloserine and beta-chloro-D-alanine against Mycobacterium tuberculosis.

Authors:  S David
Journal:  J Antimicrob Chemother       Date:  2001-02       Impact factor: 5.790

Review 3.  Scaling up interventions to achieve global tuberculosis control: progress and new developments.

Authors:  Mario Raviglione; Ben Marais; Katherine Floyd; Knut Lönnroth; Haileyesus Getahun; Giovanni B Migliori; Anthony D Harries; Paul Nunn; Christian Lienhardt; Steve Graham; Jeremiah Chakaya; Karin Weyer; Stewart Cole; Stefan H E Kaufmann; Alimuddin Zumla
Journal:  Lancet       Date:  2012-05-19       Impact factor: 79.321

4.  Synergic activity of teicoplanin and ethambutol against Mycobacterium tuberculosis.

Authors:  T M Arain; B P Goldstein; R Scotti; A Resconi
Journal:  J Antimicrob Chemother       Date:  1994-02       Impact factor: 5.790

5.  Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study.

Authors:  Tracy Dalton; Peter Cegielski; Somsak Akksilp; Luis Asencios; Janice Campos Caoili; Sang-Nae Cho; Vladislav V Erokhin; Julia Ershova; Ma Tarcela Gler; Boris Y Kazennyy; Hee Jin Kim; Kai Kliiman; Ekaterina Kurbatova; Charlotte Kvasnovsky; Vaira Leimane; Martie van der Walt; Laura E Via; Grigory V Volchenkov; Martin A Yagui; Hyungseok Kang; Rattanawadee Akksilp; Wanlaya Sitti; Wanpen Wattanaamornkiet; Sofia N Andreevskaya; Larisa N Chernousova; Olga V Demikhova; Elena E Larionova; Tatyana G Smirnova; Irina A Vasilieva; Alena V Vorobyeva; Clifton E Barry; Ying Cai; Isdore C Shamputa; Jaime Bayona; Carmen Contreras; Cesar Bonilla; Oswaldo Jave; Jeannette Brand; Joey Lancaster; Ronel Odendaal; Michael P Chen; Lois Diem; Beverly Metchock; Kathrine Tan; Allison Taylor; Melanie Wolfgang; Eunjin Cho; Seok Yong Eum; Hyun Kyung Kwak; Jiim Lee; Jongseok Lee; Seonyeong Min; Irina Degtyareva; Evgenia S Nemtsova; Tatiana Khorosheva; Elena V Kyryanova; Grace Egos; Ma Therese C Perez; Thelma Tupasi; Soo Hee Hwang; Chang-ki Kim; Su Young Kim; Hee Jeong Lee; Liga Kuksa; Inga Norvaisha; Girts Skenders; Ingrida Sture; Tiina Kummik; Tatiana Kuznetsova; Tatiana Somova; Klavdia Levina; Gustavo Pariona; Gloria Yale; Carmen Suarez; Eddy Valencia; Piret Viiklepp
Journal:  Lancet       Date:  2012-08-30       Impact factor: 79.321

6.  Inactivation of tesA reduces cell wall lipid production and increases drug susceptibility in mycobacteria.

Authors:  Sivagami Sundaram Chavadi; Uthamaphani R Edupuganti; Olivia Vergnolle; Itrat Fatima; Shaneen M Singh; Clifford E Soll; Luis E N Quadri
Journal:  J Biol Chem       Date:  2011-05-18       Impact factor: 5.157

7.  Distribution of phthiocerol diester, phenolic mycosides and related compounds in mycobacteria.

Authors:  M Daffé; M A Laneelle
Journal:  J Gen Microbiol       Date:  1988-07

8.  Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages.

Authors:  N Mor; J Vanderkolk; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

9.  Requirement for kasB in Mycobacterium mycolic acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy.

Authors:  Lian-Yong Gao; Francoise Laval; Elise H Lawson; Richard K Groger; Andy Woodruff; J Hiroshi Morisaki; Jeffery S Cox; Mamadou Daffe; Eric J Brown
Journal:  Mol Microbiol       Date:  2003-09       Impact factor: 3.501

10.  Keto-mycolic acid-dependent pellicle formation confers tolerance to drug-sensitive Mycobacterium tuberculosis.

Authors:  Dhinakaran Sambandan; Dee N Dao; Brian C Weinrick; Catherine Vilchèze; Sudagar S Gurcha; Anil Ojha; Laurent Kremer; Gurdyal S Besra; Graham F Hatfull; William R Jacobs
Journal:  mBio       Date:  2013-05-07       Impact factor: 7.867
View more
  12 in total

Review 1.  Esx Systems and the Mycobacterial Cell Envelope: What's the Connection?

Authors:  Rachel E Bosserman; Patricia A Champion
Journal:  J Bacteriol       Date:  2017-08-08       Impact factor: 3.490

2.  Total Synthesis of Tetrahydrolipstatin, Its Derivatives, and Evaluation of Their Ability to Potentiate Multiple Antibiotic Classes against Mycobacterium Species.

Authors:  Saniya S Khan; Thanuja D Sudasinghe; Alexander D Landgraf; Donald R Ronning; Steven J Sucheck
Journal:  ACS Infect Dis       Date:  2021-09-03       Impact factor: 5.578

3.  Effects of Lipid-Lowering Drugs on Vancomycin Susceptibility of Mycobacteria.

Authors:  Céline Rens; Françoise Laval; Mamadou Daffé; Olivier Denis; Rosangela Frita; Alain Baulard; Ruddy Wattiez; Philippe Lefèvre; Véronique Fontaine
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  Pleiotropic consequences of gene knockouts in the phthiocerol dimycocerosate and phenolic glycolipid biosynthetic gene cluster of the opportunistic human pathogen Mycobacterium marinum.

Authors:  Poornima Mohandas; William C Budell; Emily Mueller; Andrew Au; Glennon V Bythrow; Luis E N Quadri
Journal:  FEMS Microbiol Lett       Date:  2016-01-26       Impact factor: 2.742

5.  Aloe Emodin Reduces Phthiodiolone Dimycocerosate Potentiating Vancomycin Susceptibility on Mycobacteria.

Authors:  Céline Rens; Pieter-Jan Ceyssens; Françoise Laval; Philippe Lefèvre; Vanessa Mathys; Mamadou Daffé; Véronique Fontaine
Journal:  Indian J Microbiol       Date:  2018-05-04       Impact factor: 2.461

6.  A Fluorescent Probe for Detecting Mycobacterium tuberculosis and Identifying Genes Critical for Cell Entry.

Authors:  Dong Yang; Feng Ding; Katsuhiko Mitachi; Michio Kurosu; Richard E Lee; Ying Kong
Journal:  Front Microbiol       Date:  2016-12-20       Impact factor: 5.640

7.  Efficacy of β-lactam/β-lactamase inhibitor combination is linked to WhiB4-mediated changes in redox physiology of Mycobacterium tuberculosis.

Authors:  Saurabh Mishra; Prashant Shukla; Ashima Bhaskar; Kushi Anand; Priyanka Baloni; Rajiv Kumar Jha; Abhilash Mohan; Raju S Rajmani; Valakunja Nagaraja; Nagasuma Chandra; Amit Singh
Journal:  Elife       Date:  2017-05-26       Impact factor: 8.140

8.  Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes.

Authors:  Dimitrios Evangelopoulos; Gareth A Prosser; Angela Rodgers; Belinda M Dagg; Bhagwati Khatri; Mei Mei Ho; Maximiliano G Gutierrez; Teresa Cortes; Luiz Pedro S de Carvalho
Journal:  Nat Commun       Date:  2019-09-13       Impact factor: 14.919

9.  Mycobacterium tuberculosis Rv1152 is a Novel GntR Family Transcriptional Regulator Involved in Intrinsic Vancomycin Resistance and is a Potential Vancomycin Adjuvant Target.

Authors:  Jie Zeng; Wanyan Deng; Wenmin Yang; Hongping Luo; Xiangke Duan; Longxiang Xie; Ping Li; Rui Wang; Tiwei Fu; Abualgasim Elgaili Abdalla; Jianping Xie
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

10.  Altered Mycobacterium tuberculosis Cell Wall Metabolism and Physiology Associated With RpoB Mutation H526D.

Authors:  Victoria L Campodónico; Dalin Rifat; Yu-Min Chuang; Thomas R Ioerger; Petros C Karakousis
Journal:  Front Microbiol       Date:  2018-03-19       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.